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The epidermal growth factor (EGFR) has served as an attractive bull’s-eye for targeted cancer therapies. 
Although the importance of EGFR as an oncogenic tyrosine kinase seems well established, a report by 
Weihua et al. in this issue of Cancer Cell adds a new wrinkle to the role of EGFR in cancer. In this study, the 
authors demonstrate that EGFR facilitates glucose transport into cells by associating with and stabilizing 
a sodium/glucose cotransporter (SGLT1). Additionally, they find that this function does not require EGFR 
kinase activity. These results point to a new kinase-independent role for EGFR in promoting metabolic 
homeostasis in cancer cells.Therapies aimed at blocking epidermal 
growth factor receptor (EGFR) function 
have been sought since the 1980s, when 
Mendelsohn and colleagues showed that 
antibodies targeting this receptor effec-
tively blocked the growth of cancer cells 
(Kawamoto et al., 1983). Over the past 20 
years, these efforts have only continued 
to grow and accelerate. There are now 
several antibody and small-molecule 
inhibitors directed against EGFR that are 
actively being developed by biotechnol-
ogy and pharmaceutical companies as 
cancer therapeutics.
EGFR has historically been an attrac-
tive drug target because it is widely 
expressed in many cancers, and it has 
well-documented oncogenic activity. 
Although small-molecule tyrosine kinase 
inhibitors (TKIs) such as erlotinib (Tar-
ceva) and gefitinib (Iressa) have impres-
sive clinical activity in a small subset of 
non-small-cell lung cancers (NSCLCs), 
it is somewhat surprising that they have 
almost no clinical activity in the major-
ity of cancers that have high expression 
of EGFR (Eberhard et al., 2008). Thus, 
many espouse the concept that can-
cers responding to these inhibitors are 
“addicted” to EGFR signaling, and EGFR 
tyrosine kinase is necessary for their 
survival likely because it is the chief acti-
vator of critical downstream survival and 
growth signals such as p42/44 MAPK and 
PI3K/AKT pathways (Engelman, 2007; 
Sharma et al., 2007). Thus, when EGFR 
signaling is aborted, these pathways are 
terminated and the cancers undergo mas-
sive apoptosis. Although this explanation 
may be satisfactory, it does not explain why EGFR is highly expressed in so many 
cancers, and if it has an important role in 
those cancers.
In this issue of Cancer Cell, a study by 
Weihua et al. (2008) begins to elucidate 
a novel role for EGFR in cancers. In this 
study, they observed that EGFR main-
tains cellular homeostasis in cancers by 
a mechanism beyond its traditional role 
as an initiator and transmitter of signal 
transduction. They find that EGFR physi-
cally associates with and stabilizes the 
sodium/glucose cotransporter (SGLT1) 
to promote glucose uptake into cancer 
cells. Their first clue that EGFR impacts 
cells beyond its tyrosine kinase activ-
ity was the finding in PC-3MM2 pros-
tate cancer cells that downregulation 
Figure 1. EGFR Facilitates Glucose Trans-
port
This cartoon depicts two functions of EGFR. (Left) 
EGFR homodimerizes or heterodimerizes with oth-
er ERBB family members to promote downstream 
growth and survival signals. (Right) EGFR binds to 
SGLT1 and stabilizes its expression to promote 
glucose uptake.Cancerof EGFR with siRNA led to substantial 
cell death, but EGFR kinase inhibition 
did not. Indeed, the cell death was res-
cued by expression of either wild-type 
EGFR or a kinase-dead EGFR mutant. 
Additionally, the cell death induced by 
EGFR knockdown had the hallmarks 
of autophagy, not apoptosis, and was 
actually associated with an increase in 
AKT and p42/44 MAPK signaling. Thus, 
this pointed to a critical function for 
EGFR beyond its kinase activity, and the 
dependence on EGFR did not mirror the 
addiction models observed in other can-
cers such as EGFR mutant NSCLCs. The 
authors demonstrated that the extracel-
lular domain of EGFR associates with 
the SGLT1, and stable SGLT1 expres-
sion required EGFR expression. Indeed, 
downregulation of EGFR led to loss of 
SGLT1 expression and lower intracellu-
lar glucose levels. In fact, increasing glu-
cose levels in the culture media bathing 
the cells abrogated the death induced 
by EGFR knockdown. Thus, these stud-
ies suggest that EGFR functions not 
only as an important instigator of signal 
transduction cascades, but also as an 
integral component of an active glucose 
transport system (Figure 1).
This study has several important 
implications that may impact thera-
peutic approaches to cancer. Do EGFR 
TKIs and/or antibodies that are clini-
cally effective work, in part, by disrupt-
ing the association between EGFR and 
SGLT1? Although definitive studies have 
not yet been done, this seems less likely 
to account for the activity of small-mol-
ecule TKIs. Inhibiting EGFR kinase activ- Cell 13, May 2008 ©2008 Elsevier Inc. 375
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with SGLT1 or decrease basal intracellu-
lar glucose levels. Furthermore, the effi-
cacy of EGFR TKIs appears to be limited 
to cancers with classic EGFR oncogene 
addiction in cancers harboring EGFR 
mutations and/or amplifications that, upon 
treatment with TKIs, have dramatic down-
modulation of downstream cell survival 
signaling pathways.
In contrast to TKIs, it is less clear how 
antibodies targeting EGFR function to 
kill cancer cells. They have been thought 
to function by disrupting signaling and/
or promoting cell-mediated cytotoxicity. 
However, at this point, one cannot rule 
out that antibody therapies may work, in 
part, by disrupting the physical interac-
tion between EGFR and SGLT1, espe-
cially since both cetuximab (Erbitux) and 
SGLT1 appear to interact with the extra-
cellular domain of EGFR. The EGFR anti-
body cetuximab is most effective in col-
orectal cancers that express high levels 
of EGFR ligand and have wild-type K-Ras 
(Khambata-Ford et al., 2007; Lievre et 
al., 2006). These observations suggest 
that these cancers have activation of 
EGFR kinase activity, thereby supporting 
the classic oncogene addiction model. 
Indeed, the absence of K-Ras mutations 
also identifies NSCLCs most likely to 
respond to EGFR TKIs (Pao et al., 2005). 
However, we do not yet know how the 
presence of EGFR ligands and poten-
tial dimerization partners affects binding 
between EGFR and SGLT1, and perhaps 
these biomarkers for cetuximab activity 
also predict an integral role for EGFR in 
active glucose transport. There are many 
potential molecular mechanisms that 
could describe how the clinical activity 
of antibody therapies is achieved by per-
turbing the interaction between EGFR 
and SGLT1. It will be interesting to learn 376 Cancer Cell 13, May 2008 ©2008 Elseviif cetuximab or other anti-EGFR antibod-
ies affect the ability of EGFR to associate 
with SGLT1, and if some of their biologi-
cal activity is achieved by disrupting this 
interaction.
This study also serves as another 
example of the intersection between 
traditional signaling cascades and basic 
cellular metabolism. It is reminiscent 
of the findings that intracellular energy 
and amino acids regulate mTOR signal-
ing (Byfield et al., 2005; Corradetti et 
al., 2004; Nobukuni et al., 2005; Shaw 
et al., 2004), and the recent observation 
that tyrosine phosphorylation signaling 
affects the activity of the M2 isoform 
of pyruvate kinase (PKM2) (Christofk 
et al., 2008). The interaction between 
EGFR and SGLT1 appears to be another 
adaptation by eukaryotic cells to coor-
dinate cellular growth and division with 
nutrient uptake. However, further study 
is required to understand how signal-
ing and glucose uptake are coupled 
and regulated by this newly discovered 
complex. Furthermore, this new dimen-
sion of EGFR function seems ripe for 
therapeutic intervention. Disrupting the 
association between EGFR and SGLT1 
may affect intracellular glucose levels, 
and this in turn may affect the cancer’s 
ability to withstand stresses (e.g., che-
motherapy or radiation therapy). Since 
this function of EGFR directly impacts 
glucose uptake, one might expect that 
PET scans would be a useful biomarker 
for a therapy aimed toward inhibiting the 
binding of EGFR to SGLT1. Indeed, com-
bining such a therapy with autophagy 
inhibitors or other drugs that meta-
bolically stress cancer cells might have 
impressive clinical activity. It is clear that 
the findings of this exciting new study 
will broaden how we develop strategies 
to target EGFR. Furthermore, when we er Inc.devise therapies to inhibit EGFR, we will 
consider its role not only as a kinase, but 
also as a sweetener.
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